These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 1468773)

  • 1. Immunoreactivity with monoclonal antibody A-80 and nuclear DNA content in benign and malignant human breast disease.
    Eriksson E; Schimmelpenning H; Silfverswärd C; Auer G
    Hum Pathol; 1992 Dec; 23(12):1366-72. PubMed ID: 1468773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical expression of the mutant p53 protein and nuclear DNA content during the transition from benign to malignant breast disease.
    Eriksson ET; Schimmelpenning H; Aspenblad U; Zetterberg A; Auer GU
    Hum Pathol; 1994 Nov; 25(11):1228-33. PubMed ID: 7959668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of the c-erbB-2 proto-oncogene product and nuclear DNA content in benign and malignant human breast parenchyma.
    Schimmelpenning H; Eriksson ET; Falkmer UG; Azavedo E; Svane G; Auer GU
    Virchows Arch A Pathol Anat Histopathol; 1992; 420(5):433-40. PubMed ID: 1350695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of tumor-associated antigen (DF3) in atypical hyperplasias and in situ carcinomas of the human breast.
    Ohuchi N; Page DL; Merino MJ; Viglione MJ; Kufe DW; Schlom J
    J Natl Cancer Inst; 1987 Jul; 79(1):109-17. PubMed ID: 3298784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Image cytophotometric DNA analysis of atypical hyperplasias and intraductal carcinomas of the breast.
    Crissman JD; Visscher DW; Kubus J
    Arch Pathol Lab Med; 1990 Dec; 114(12):1249-53. PubMed ID: 2174672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
    Ottesen GL
    APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of c-erb B-2 protein and DNA ploidy in breast carcinogenesis.
    Schmitt FC; Figueiredo P; Lacerda M
    Arch Pathol Lab Med; 1995 Sep; 119(9):815-20. PubMed ID: 7668939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin D1 gene amplification and protein expression in benign breast disease and breast carcinoma.
    Zhu XL; Hartwick W; Rohan T; Kandel R
    Mod Pathol; 1998 Nov; 11(11):1082-8. PubMed ID: 9831206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The DNA profile of breast cancer in situ.
    Pallis L; Skoog L; Falkmer U; Wilking N; Rutquist LE; Auer G; Cedermark B
    Eur J Surg Oncol; 1992 Apr; 18(2):108-11. PubMed ID: 1582502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of cytometric analysis for distinction of intraductal carcinoma of the breast.
    Fisher ER; Siderits R
    Breast Cancer Res Treat; 1992; 21(3):165-72. PubMed ID: 1325216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunocytochemical identification of cell types in benign and malignant breast diseases: variations in cell markers accompany the malignant state.
    Rudland PS; Leinster SJ; Winstanley J; Green B; Atkinson M; Zakhour HD
    J Histochem Cytochem; 1993 Apr; 41(4):543-53. PubMed ID: 8450194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flow cytometric study of DNA distribution in cytopunctures of benign and malignant breast lesions.
    Spyratos F; Briffod M; Gentile A; Brunet M; Brault C; Desplaces A
    Anal Quant Cytol Histol; 1987 Dec; 9(6):485-94. PubMed ID: 3435626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytofluorometric nuclear DNA content analysis of breast tissues after frozen section diagnosis.
    Sato T; Chiba M; Kamiyama T; Miura T; Kanagawa Y; Nakano K; Sato T; Ishikawa T; Nozaka H; Kogawa R; Yasujima M
    Anal Quant Cytol Histol; 2000 Feb; 22(1):70-5. PubMed ID: 10696463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokeratin 5/6 immunohistochemistry assists the differential diagnosis of atypical proliferations of the breast.
    Otterbach F; Bànkfalvi A; Bergner S; Decker T; Krech R; Boecker W
    Histopathology; 2000 Sep; 37(3):232-40. PubMed ID: 10971699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of the combined assessment of proliferating cell nuclear antigen immunostaining and nuclear DNA content in invasive human mammary carcinomas.
    Schimmelpenning H; Eriksson ET; Franzén B; Zetterberg A; Auer GU
    Virchows Arch A Pathol Anat Histopathol; 1993; 423(4):273-9. PubMed ID: 7901939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flow cytometric DNA/cytokeratin analysis of bladder lavage: methodical aspects and clinical implications.
    Liedl T
    Urol Int; 1995; 54(1):22-47. PubMed ID: 7770998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical c-erbB-2 protooncogene expression and nuclear DNA content in human mammary carcinoma in situ.
    Schimmelpenning H; Eriksson ET; Pallis L; Skoog L; Cedermark B; Auer GU
    Am J Clin Pathol; 1992 May; 97(5 Suppl 1):S48-52. PubMed ID: 1374218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 protein expression and nuclear DNA content in breast intraductal proliferations.
    Schmitt FC; Leal C; Lopes C
    J Pathol; 1995 Jul; 176(3):233-41. PubMed ID: 7674086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of clusterin in human breast carcinoma.
    Redondo M; Villar E; Torres-Muñoz J; Tellez T; Morell M; Petito CK
    Am J Pathol; 2000 Aug; 157(2):393-9. PubMed ID: 10934144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytological criteria for the diagnosis of intraductal hyperplasia, ductal carcinoma in situ, and invasive carcinoma of the breast.
    Bofin AM; Lydersen S; Hagmar BM
    Diagn Cytopathol; 2004 Oct; 31(4):207-15. PubMed ID: 15452908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.